• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

New Lancet Study: Second Hand Smoke Increases Heart Attack Risk; Nymox (NASDAQ: NYMX) TobacAlert(TM) Product Detects Second-Hand Smoke Exposure

Posted on: Tuesday, 22 August 2006, 15:00 CDT

Nymox Pharmaceutical's (NASDAQ:NYMX) TobacAlert(TM) product provides an easy-to-use, cost-effective means of on-site testing for second-hand smoke exposure without the need for instruments, equipment or specialized training. A new study published in The Lancet (Aug.19, 2006) from McMaster University concluded that exposure to second hand smoke increased the risk of heart attack in both former smokers and nonsmokers. People in the study with the highest levels of second-hand smoke exposure (22 hours or more per week) had a 45 percent increased risk of heart attack. The findings were based on data from 52 countries and over 27,000 individuals.

Second-hand smoke poses a serious and pervasive health risk to children and adults according to a new comprehensive report from the U.S. Surgeon General, The Health Consequences of Involuntary Exposure to Tobacco Smoke. The report highlights how vulnerable children in particular are to second-hand smoke. Children exposed to secondhand smoke are at an increased risk for sudden infant death syndrome (SIDS), acute respiratory infections, ear problems, worsening of allergies and more severe asthma. The report also links second-hand smoke to coronary heart disease and lung cancer in adults and notes that even a brief exposure to second-hand smoke has immediate adverse effects on a person's cardiovascular system.

TobacAlert(TM) measures levels of cotinine, a metabolite of nicotine described in the Surgeon General's Report as "the biomarker of choice for assessing secondhand smoke exposure." Researchers at the Centers for Disease Control and Prevention (CDC) recently reported positive results using Nymox TobacAlert(TM) technology combined with complex laboratory testing (liquid chromatography-mass spectrometry) used in the CDC laboratory (Journal of Analytical Toxicology November/December, 2005; 29: 814-818).

More information is available at www.tobacalert.com.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Source: Business Wire

More News in this Category